David O Walterhouse1, Alberto S Pappo2, Jane L Meza3, John C Breneman4, Andrea Hayes-Jordan5, David M Parham6, Timothy P Cripe7, James R Anderson8, William H Meyer9, Douglas S Hawkins10. 1. Division of Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Division of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Biostatistics, University of Nebraska Medical Center College of Public Health, Omaha, Nebraska. 4. Division of Radiation Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 5. Division of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California. 7. Division of Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children's Hospital, Columbus, Ohio. 8. Oncology Clinical Research, Merck Research Laboratories, North Wales, Pennsylvania. 9. Jimmy Everest Section of Pediatric Hematology and Oncology, University of Oklahoma School of Medicine, Oklahoma City, Oklahoma. 10. Division of Hematology/Oncology, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.
Abstract
BACKGROUND: Failure-free survival (FFS) and overall survival (OS) rates were found to improve on Intergroup Rhabdomyosarcoma Study (IRS) IV (IRS-IV) compared with IRS-III for patients with subset 2 (IRS stage 1, group III nonorbit or stage 3, group I/II) low-risk embryonal rhabdomyosarcoma with the addition of cyclophosphamide (total cumulative cyclophosphamide dose of 26.4 g/m2 ) to the combination of vincristine and dactinomycin (VAC). The goal of Children's Oncology Group ARST0331 for subset 2 low-risk patients was to reduce the total cumulative cyclophosphamide dose without compromising FFS. METHODS: Therapy included 4 cycles of VAC (total cumulative cyclophosphamide dose of 4.8 g/m2 ) followed by 12 cycles of vincristine and dactinomycin over 46 weeks. Patients with group II or III tumors received radiotherapy, except for girls with group III vaginal tumors who enrolled before September 2009 and achieved a complete response with chemotherapy with or without delayed surgical resection. RESULTS: Among 66 eligible patients who were followed for a median of 3.5 years, there were 20 failures versus 10.53 expected failures. The estimated 3-year FFS and OS rates were 70% (95% confidence interval [95% CI], 57%-80%) and 92% (95% CI, 83%-97%), respectively. The estimated 3-year FFS rate was 57% (95% CI, 33%-75%) for girls with subset 2 genital tract embryonal rhabdomyosarcoma (21 patients) and 77% (95% CI, 61%-87%) for all other subset 2 patients (45 patients) (P = .02). CONCLUSIONS: The authors observed suboptimal FFS among patients with subset 2 low-risk rhabdomyosarcoma using reduced total cyclophosphamide. Eliminating radiotherapy for girls with group III vaginal tumors in combination with reduced total cyclophosphamide appeared to contribute to the suboptimal outcome. Cancer 2017;123:2368-2375.
BACKGROUND: Failure-free survival (FFS) and overall survival (OS) rates were found to improve on Intergroup Rhabdomyosarcoma Study (IRS) IV (IRS-IV) compared with IRS-III for patients with subset 2 (IRS stage 1, group III nonorbit or stage 3, group I/II) low-risk embryonal rhabdomyosarcoma with the addition of cyclophosphamide (total cumulative cyclophosphamide dose of 26.4 g/m2 ) to the combination of vincristine and dactinomycin (VAC). The goal of Children's Oncology Group ARST0331 for subset 2 low-risk patients was to reduce the total cumulative cyclophosphamide dose without compromising FFS. METHODS: Therapy included 4 cycles of VAC (total cumulative cyclophosphamide dose of 4.8 g/m2 ) followed by 12 cycles of vincristine and dactinomycin over 46 weeks. Patients with group II or III tumors received radiotherapy, except for girls with group III vaginal tumors who enrolled before September 2009 and achieved a complete response with chemotherapy with or without delayed surgical resection. RESULTS: Among 66 eligible patients who were followed for a median of 3.5 years, there were 20 failures versus 10.53 expected failures. The estimated 3-year FFS and OS rates were 70% (95% confidence interval [95% CI], 57%-80%) and 92% (95% CI, 83%-97%), respectively. The estimated 3-year FFS rate was 57% (95% CI, 33%-75%) for girls with subset 2 genital tract embryonal rhabdomyosarcoma (21 patients) and 77% (95% CI, 61%-87%) for all other subset 2 patients (45 patients) (P = .02). CONCLUSIONS: The authors observed suboptimal FFS among patients with subset 2 low-risk rhabdomyosarcoma using reduced total cyclophosphamide. Eliminating radiotherapy for girls with group III vaginal tumors in combination with reduced total cyclophosphamide appeared to contribute to the suboptimal outcome. Cancer 2017;123:2368-2375.
Authors: Daniel M Green; Wei Liu; William H Kutteh; Raymond W Ke; Kyla C Shelton; Charles A Sklar; Wassim Chemaitilly; Ching-Hon Pui; James L Klosky; Sheri L Spunt; Monika L Metzger; DeoKumar Srivastava; Kirsten K Ness; Leslie L Robison; Melissa M Hudson Journal: Lancet Oncol Date: 2014-09-16 Impact factor: 41.316
Authors: W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: R Beverly Raney; David O Walterhouse; Jane L Meza; Richard J Andrassy; John C Breneman; William M Crist; Harold M Maurer; William H Meyer; David M Parham; James R Anderson Journal: J Clin Oncol Date: 2011-02-28 Impact factor: 44.544
Authors: A S Pappo; J R Anderson; W M Crist; M D Wharam; P P Breitfeld; D Hawkins; R B Raney; R B Womer; D M Parham; S J Qualman; H E Grier Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: Smita Bhatia; Mark D Krailo; Zhengjia Chen; Laura Burden; Frederic B Askin; Paul S Dickman; Holcombe E Grier; Michael P Link; Paul A Meyers; Elizabeth J Perlman; Aaron R Rausen; Leslie L Robison; Teresa J Vietti; James S Miser Journal: Blood Date: 2006-09-19 Impact factor: 22.113
Authors: David O Walterhouse; Jane L Meza; John C Breneman; Sarah S Donaldson; Andrea Hayes-Jordan; Alberto S Pappo; Carola Arndt; R Beverly Raney; William H Meyer; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2011-02-04 Impact factor: 3.167
Authors: Christopher L Tinkle; Alberto Pappo; Jianrong Wu; Shenghua Mao; Chia-Ho Hua; Barry L Shulkin; M Beth McCarville; Sue C Kaste; Andrew M Davidoff; Armita Bahrami; Daniel M Green; Kirsten K Ness; Thomas E Merchant; Sheri L Spunt; Matthew J Krasin Journal: Int J Radiat Oncol Biol Phys Date: 2020-01-25 Impact factor: 7.038
Authors: Dana L Casey; Yueh-Yun Chi; Sarah S Donaldson; Douglas S Hawkins; Jing Tian; Carola A Arndt; David A Rodeberg; Jonathan C Routh; Timothy B Lautz; Abha A Gupta; Torunn I Yock; Suzanne L Wolden Journal: Cancer Date: 2019-06-07 Impact factor: 6.860
Authors: Julie A Bradley; Mark L Kayton; Yueh-Yun Chi; Douglas S Hawkins; Jing Tian; John Breneman; Suzanne L Wolden; David Walterhouse; David A Rodeberg; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-20 Impact factor: 7.038
Authors: Douglas S Hawkins; Yueh-Yun Chi; James R Anderson; Jing Tian; Carola A S Arndt; Lisa Bomgaars; Sarah S Donaldson; Andrea Hayes-Jordan; Leo Mascarenhas; Mary Beth McCarville; Jeannine S McCune; Geoff McCowage; Lynn Million; Carol D Morris; David M Parham; David A Rodeberg; Erin R Rudzinski; Margarett Shnorhavorian; Sheri L Spunt; Stephen X Skapek; Lisa A Teot; Suzanne Wolden; Torunn I Yock; William H Meyer Journal: J Clin Oncol Date: 2018-08-09 Impact factor: 44.544
Authors: Veronique Minard-Colin; David Walterhouse; Gianni Bisogno; Helene Martelli; James Anderson; David A Rodeberg; Andrea Ferrari; Meriel Jenney; Suzanne Wolden; Gianluca De Salvo; Carola Arndt; Johannes H M Merks; Soledad Gallego; Dominique Schwob; Christine Haie-Meder; Christophe Bergeron; Michael C G Stevens; Odile Oberlin; Douglas Hawkins Journal: Pediatr Blood Cancer Date: 2018-05-21 Impact factor: 3.167
Authors: Ritesh K Srivastava; Changzhao Li; Jasim Khan; Nilam Sanjib Banerjee; Louise T Chow; Mohammad Athar Journal: Proc Natl Acad Sci U S A Date: 2019-11-15 Impact factor: 11.205
Authors: David O Walterhouse; Donald A Barkauskas; David Hall; Andrea Ferrari; Gian Luca De Salvo; Ewa Koscielniak; Michael C G Stevens; Hélène Martelli; Guido Seitz; David A Rodeberg; Margarett Shnorhavorian; Roshni Dasgupta; John C Breneman; James R Anderson; Christophe Bergeron; Gianni Bisogno; William H Meyer; Douglas S Hawkins; Veronique Minard-Colin Journal: J Clin Oncol Date: 2018-10-23 Impact factor: 44.544
Authors: Jonathan C Routh; Roshni Dasgupta; Yueh-Yun Chi; Margarett Shnorhavorian; Jing Tian; David O Walterhouse; John Breneman; Suzanne L Wolden; Carola A Arndt; Douglas S Hawkins; David A Rodeberg Journal: Int J Cancer Date: 2020-07-11 Impact factor: 7.396